Dyne Therapeutics, Inc. ( DYN) - Key Metrics
DYN Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $0 | -$1.08 | -$0.79 | -$0.80 |
| 2026Q1 | $0 | -$0.73 | -$0.88 | -$0.88 |
| 2025Q4 | $0 | -$0.87 | -$0.87 | -$0.87 |
| 2025Q3 | $0 | -$0.76 | -$0.64 | -$0.78 |
| 2025Q2 | $0 | -$0.97 | -$0.83 | -$0.83 |
DYN Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | -5.14 |
| 2026Q1 | 0% | -6.21 |
| 2025Q4 | 0% | -6.43 |
| 2025Q3 | 0% | -4.16 |
| 2025Q2 | 0% | -2.45 |
DYN
Price: $15.29
52 week price:
Earnings Per Share: -3.28 USD
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 169300
Ebitda: 950.0 millionMarket Capitalization: 2.9 billion